Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 601–700 of 1,000
Lin, D. I., Killian, J. K., Venstrom, J. M., Ramkissoon, S. H., Ross, J. S., & Elvin, J. A. (2020) · Modern Pathology · doi:10.1038/s41379-020-00699-1 · Cited by 31
Molecular Mechanisms to Target Cellular Senescence in Hepatocellular Carcinoma
Mittermeier, C., Konopa, A., & Muehlich, S. (2020) · Cells · doi:10.3390/cells9122540 · Cited by 31
Conley, C. C., McIntyre, M., Pensak, N. A., Lynce, F. C., Graham, D. M. A., Ismail-Khan, R. R., Lopez, K., Vadaparampil, S. T., & O’Neill, S. C. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06518-2 · Cited by 27
Xu, J., Xiao, X., Yan, B., Yuan, Q., Dong, X., Du, Q., Zhang, J., Shan, L., Ding, Z., Zhou, L., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02468-3 · Cited by 28
CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Gupta, P., Narayanan, S., & Yang, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00009-2 · Cited by 36
Malorni, L., Tyekucheva, S., Hilbers, F., Ignatiadis, M., Neven, P., Colleoni, M. A., Henry, S., Ballestrero, A., Bonetti, A. V., Jérusalem, G., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.030 · Cited by 27
Self-citationPatt, D. A., Liu, X., Li, B. C., McRoy, L., Layman, R. M., & Brufsky, A. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.05.002 · Cited by 28
Finnegan, R., Elshazly, A. M., Patel, N. H., Tyutyunyk‐Massey, L., Tran, T. H., Kumarasamy, V. M., Knudsen, E. S., & Gewirtz, D. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.966441 · Cited by 27
“cancer patients diagnosed with locally advanced or metastatic disease progression following endocrine therapy, this combination therapy only modestly prolongs patient survival (30).”
BackgroundAromatase inhibitors: the journey from the state of the art to clinical open questions
Generali, D., Berardi, R., Caruso, M., Cazzaniga, M. E., Garrone, O., Minchella, I., Paris, I., Pinto, C., & Placido, S. D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249160 · Cited by 27
Emerging targeted therapies for melanoma
Johnson, D. B., Pollack, M. L. H., & Sosman, J. A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1184644 · Cited by 27
The Androgen Receptor: Is It a Promising Target?
Gucalp, A., & Traina, T. A. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5961-9 · Cited by 27
Zhang, J., Zhang, Y., Tang, S., Jiang, L., He, Q., Hamblin, L. T., He, J., Xu, Z., Wu, J., Chen, Y., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017240 · Cited by 27
Celia, C., Cristiano, M. C., Froiio, F., Francesco, M. D., d’Avanzo, N., Marzio, L. D., & Fresta, M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000121 · Cited by 28
Green, A. K., Zhou, Q. C., Iasonos, A. E., Zammarrelli, W. A., Weigelt, B., Ellenson, L. H., Chhetri-Long, R., Shah, P., Loh, J., Hom, V., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1999 · Cited by 32
Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
Schedin, T., Borges, V. F., & Shagisultanova, E. I. (2018) · International Journal of Breast Cancer · doi:10.1155/2018/7835095 · Cited by 29
Lynce, F. C., Blackburn, M. J., Zhuo, R., Gallagher, C., Hahn, O. M., Abu-Khalaf, M. M., Mohebtash, M., Wu, T., Pohlmann, P. R., Dilawari, A. A., et al. (2021) · Cancer · doi:10.1002/cncr.33620 · Cited by 26
Lee, H., Chu, K., Moon, E., & Quan, F. (2021) · Journal of Cancer · doi:10.7150/jca.60027 · Cited by 27
New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies
Lanza, O., Ferrera, A., Reale, S., Solfanelli, G., Petrungaro, M., Tini, G., Volpe, M., & Battistoni, A. (2022) · Medical Sciences · doi:10.3390/medsci10020027 · Cited by 30
Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism
Zuo, Q., Park, N. H., Lee, J. K., & Madak‐Erdogan, Z. (2022) · Nutrients · doi:10.3390/nu14122376 · Cited by 29
PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity
Wang, S., Liu, X., Zhou, T., Li, J., Lin, Y., Zhou, A., Huang, J. M., Zhao, J., Cai, J., Cai, X., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00744-y · Cited by 26
Bardia, A., Mayer, I. A., Winer, E. P., Linden, H. M., Ma, C. X., Parker, B. A., Bellet, M., Arteaga, C. L., Cheeti, S., Gates, M. R., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06797-9 · Cited by 26
Low, J. L., Lim, E. H., Bharwani, L. D., Wong, A. L. A., Wong, K., Ow, S. G. W., Lim, S. E., Lee, M., Choo, J. R. E., Lim, J. S. J., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221139678 · Cited by 26
How I treat endocrine-dependent metastatic breast cancer
Gombos, A., Gonçalvès, A., Curigliano, G., Bartsch, R., Kyte, J., Ignatiadis, M., & Awada, A. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100882 · Cited by 26
Rugo, H. S., Liu, X., Li, B. C., McRoy, L., Layman, R. M., & Brufsky, A. (2023) · The Breast · doi:10.1016/j.breast.2023.03.015 · Cited by 27
Determinants of response to CDK4/6 inhibitors in the real-world setting
Witkiewicz, A. K., Schultz, E., Wang, J., Hamilton, D., Levine, E. G., O’Connor, T. L., & Knudsen, E. S. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00438-0 · Cited by 29
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
Recent advancements of hydrogels in immunotherapy: Breast cancer treatment
Mondal, J., Chakraborty, K., Bunggulawa, E. J., An, J. M., Revuri, V., Nurunnabi, M., & Lee, Y.-K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.003 · Cited by 26
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions
Costa, R. L. B., Santa-Maria, C. A., Rossi, G., Carneiro, B. A., Chae, Y. K., Gradishar, W. J., Giles, F. J., & Cristofanilli, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13778 · Cited by 28
Self-citationWebber, J. T., Ranall, M. V., Kaushik, S., & Bandyopadhyay, S. (2018) · Cell Systems · doi:10.1016/j.cels.2018.10.001 · Cited by 27
Curigliano, G., de Azambuja, E., Lenihan, D. J., Calabró, M. G., Cardinale, D. M., & Cipolla, C. M. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0773 · Cited by 26
Reinhardt, F., Franken, A., Meier-Stiegen, F., Driemel, C., Stoecklein, N. H., Fischer, J., Niederacher, D., Ruckhaeberle, E., Fehm, T. N., & Neubauer, H. J. (2019) · Cancers · doi:10.3390/cancers11070903 · Cited by 26
ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
Sava, G. P., Fan, H., Fisher, R. A., Lusvarghi, S., Pancholi, S., Ambudkar, S. V., Martin, L., Coombes, R. C., Buluwela, L., & Ali, S. (2019) · Oncogene · doi:10.1038/s41388-019-1008-y · Cited by 28
“Cell cycle deregulation is a common feature of cancer and a number of cell cycle CDK inhibitors have been approved as cancer therapeutics, most prominently CDK4/6 inhibitors, exemplified by palbociclib, for the treatment of advanced oestrogen receptor positive (ER+) breast cancer [9].”
Palumbo, R., Torrisi, R., Sottotetti, F., Presti, D., Gambaro, A. R., Collovà, E., Ferzi, A., Agostinetto, E., Teragni, C. M., Saltalamacchia, G., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920987651 · Cited by 26
Sammons, S. L., Kornblum, N. S., & Blackwell, K. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0587-9 · Cited by 27
Shee, K., Jiang, A., Varn, F. S., Liu, S., Traphagen, N. A., Owens, P., Ma, C. X., Hoog, J., Cheng, C., Golub, T. R., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801241r · Cited by 28
A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp)
Ribaudo, G., Ongaro, A., Oselladore, E., Zagotto, G., Memo, M., & Gianoncelli, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1822209 · Cited by 25
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2021-0842 · Cited by 25
Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Firoozbakht, F., Rezaeian, I., Rueda, L. G., & Ngom, A. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04662-6 · Cited by 26
Lee, J. S., Yost, S. E., Li, S. M., Cui, Y., Frankel, P. H., Yuan, Y., Schmolze, D., Egelston, C. A., Guo, W., Murga, M., et al. (2022) · Cancers · doi:10.3390/cancers14133159 · Cited by 27
Jung, H. A., Kim, M., Kim, H. S., Kim, J.-H., Choi, Y. H., Cho, J., Park, J. H., Park, K. U., Ku, B. M., Park, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.008 · Cited by 28
Pancholi, S., Simigdala, N., Ribas, R., Schuster, E. F., Leal, M. F., Nikitorowicz-Buniak, J., Rega, C., Bihani, T., Patel, H., Johnston, S. R. D., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00483-1 · Cited by 28
Sánchez-Bayona, R., de, A. L., Gilarranz, Y. J., de Torre, A. S., Alva, M., Echavarría, I., Moreno, F., Tolosa, P., López, B. H., de Luna, A., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07324-8 · Cited by 27
Brufsky, A. (2015) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s31586 · Cited by 31
Koleva‐Kolarova, R., Oktora, M. P., Robijn, A. L., Greuter, M. J. W., Reyners, A. K. L., Buskens, E., & de Bock, G. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.001 · Cited by 25
Freedman, R. A., & Tolaney, S. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4560-6 · Cited by 28
A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers
Maximov, P. Y., Abderrahman, B., Curpan, R. F., Hawsawi, Y. M., Fan, P., & Jordan, V. C. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0416 · Cited by 29
PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.
Huang, D., Tang, L., Yang, F., Jin, J., & Guan, X. (2019) · PubMed Central · Cited by 31
Şahin, T. K., Kavgacı, G., Güven, D. C., & Aksoy, S. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102956 · Cited by 24
Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer
Mancuso, M. R., & Massarweh, S. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.001 · Cited by 25
Chirila, C., Mitra, D., Colosia, A. D., Ling, C. S., Odom, D. M., Iyer, S. S., & Kaye, J. A. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1325730 · Cited by 24
Seifert, R., Küper, A. T., Tewes, M., Heuschmid, M., Welt, A., Fendler, W. P., Herrmann, K., & Decker, T. W. (2021) · Oncology Research and Treatment · doi:10.1159/000516422 · Cited by 24
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S., Kim, G. M., Kim, T. Y., Ryu, W., Kim, J. Y., Park, H. S., Park, S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-022-01601-4 · Cited by 27
Shimomura, K., Hattori, N., Iida, N., Muranaka, Y., Sato, K., Shiraishi, Y., Arai, Y., Hama, N., Shibata, T., Narushima, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42228-z · Cited by 24
Curigliano, G., Criscitiello, C., Espósito, A., Intra, M., & Minucci, S. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1318848 · Cited by 24
PAQR4 has a tumorigenic effect in human breast cancers in association with reduced CDK4 degradation
Zhang, H., Han, R., Ling, Z., Zhang, F., Hou, Y., You, X., Huang, M., Zhao, Z., Wang, Z., & Chen, Y. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx143 · Cited by 25
ASCO 2018 highlights: metastatic breast cancer
Rinnerthaler, G., Gampenrieder, S. P., & Greil, R. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0450-9 · Cited by 24
Inoue, K., Masuda, N., Iwata, H., Takahashi, M., Ito, Y., Miyoshi, Y., Nakayama, T., Mukai, H., van der Walt, J., Mori, J., et al. (2021) · Breast Cancer · doi:10.1007/s12282-021-01239-8 · Cited by 25
Self-citationKi67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
Shao, X., Zheng, Y., Cao, W., Shen, X., Li, G., Chen, J., Huang, Y., Huang, P., Shi, L., Ye, W.-W., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1340 · Cited by 27
CDK6 Is a Therapeutic Target in Myelofibrosis
Dutta, A., Nath, D., Yang, Y., Le, B. T., & Mohi, G. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0590 · Cited by 25
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
Main, S. C., Cescon, D. W., & Bratman, S. V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.37 · Cited by 24
Raghavendra, A. S., Kettner, N. M., Kwiatkowski, D. N., Damodaran, S., Wang, Y., Ramirez, D. L., Gombos, D. S., Hunt, K. K., Shen, Y., Keyomarsi, K., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00722-1 · Cited by 24
Targeting Cyclin-Dependent Kinases in Ovarian Cancer
Zhou, Q. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1283508 · Cited by 24
Ademuyiwa, F. O., Northfelt, D., O’Connor, T. L., Levine, E. G., Luo, J. R., Tao, Y., Hoog, J., Laury, M. L., Summa, T., Hammerschmidt, T., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-022-00504-z · Cited by 23
Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition
Hu, Q., & Huang, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108939 · Cited by 26
Erk, N., Bouali, W., Genç, A. A., Salamat, Q., & Soylak, M. (2024) · ACS Omega · doi:10.1021/acsomega.4c02460 · Cited by 23
Continuous‐Flow Photochemistry: The Synthesis of Marketed Pharmaceutical Compounds
Srivastava, V., Singh, P. P., Sinha, S., Singh, P. K., & Kumar, D. (2024) · ChemistrySelect · doi:10.1002/slct.202405020 · Cited by 23
Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib
Nelson, K. L., Stenehjem, D. D., Driscoll, M., & Gilcrease, G. W. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00150 · Cited by 25
CDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats
Sacaan, A. I., Thibault, S., Hong, M., Kondegowda, N. G., Nichols, T., Li, R., Rosselot, C., Evering, W., Fenutría, R., Vitsky, A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0172 · Cited by 25
Stearns, V., Brufsky, A., Verma, S., Cotter, M. J., Lu, D. R., Dequen, F., & Joy, A. A. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.007 · Cited by 23
Self-citationPharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy
Castellví, M., Felip, E., Ezeonwumelu, I. J., Badía, R., García-Vidal, E., Pujantell, M., Gutiérrez-Chamorro, L., Teruel, I., Martínez‐Cardús, A., Clotet, B., et al. (2020) · Cancers · doi:10.3390/cancers12030713 · Cited by 25
“In this sense, the choice of highly selective CDK4/6 inhibitors as the first clinically effective CDK4/6 inhibitors developed [38,39] is of special relevance.”
BackgroundUpdate Breast Cancer 2017 – Implementation of Novel Therapies
Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., Ettl, J., et al. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-122885 · Cited by 22
Tancredi, R. J., Furlanetto, J., & Loibl, S. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0077 · Cited by 25
Self-citationMycock, K., Zhan, L., Hart, K., Taylor‐Stokes, G., Milligan, G., Atkinson, C., & Mitra, D. (2021) · Future Oncology · doi:10.2217/fon-2021-0716 · Cited by 22
CDK 4/6 inhibitors for the treatment of meningioma
Young, J. S., Kidwell, R. L., Zheng, A., Haddad, A. F., Aghi, M. K., Raleigh, D. R., Schulte, J. D., & Butowski, N. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931371 · Cited by 23
Chen, G., Sun, L., Gu, X., Ai, L., Yang, J., Zhang, Z., Hou, P., Wang, Y., Ou, X., Jiang, X., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2343-y · Cited by 22
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
Aliagas, E., Alay, A., Martínez‐Iniesta, M., Hernández-Madrigal, M., Cordero, D., Gausachs, M., Pros, E., Saigí, M., Busacca, S., Sharkley, A. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01547-y · Cited by 22
Zhao, S., Zhou, L., Dicker, D. T., Lev, A., Zhang, S., Ross, E. A., & El‐Deiry, W. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00150-8 · Cited by 24
Cottu, P. H., Ring, A. E., Abdel‐Razeq, H., Marchetti, P., Cardoso, F., Bofill, J. S., Martín, M., Menon-Singh, L., Wu, J., & Laurentiis, M. D. (2022) · The Breast · doi:10.1016/j.breast.2022.01.016 · Cited by 22
Rubovszky, G., Kocsis, J., Boér, K., Chilingirova, N. P., Dank, M., Kahán, Z., Kaidarova, D., Kövér, E., Vertáková-Krakovská, B., Máhr, K., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610383 · Cited by 24
“5 months) and improved quality of life [abemaciclib (89), palbociclib (90), ribociclib (85)].”
BackgroundA pilot study of cabergoline for the treatment of metastatic breast cancer
Costa, R. L. B., Santa-Maria, C. A., Scholtens, D. M., Jain, S., Flaum, L., Gradishar, W. J., Clevenger, C. V., & Kaklamani, V. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4370-x · Cited by 24
Campone, M., Bachelot, T., Penault-Llorca, F. M., Pallis, A. G., Agrapart, V., Pierrat, M., Poirot, C., Dubois, F., Xuereb, L., Bossard, C. J., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-03765-3 · Cited by 22
Self-citationSchuh, A., Dreau, H. M.-P., Knight, S. J. L., Ridout, K. E., Mizani, T., Vavoulis, D. V., Colling, R. T., Antoniou, P., Kvikstad, E. M., Pentony, M. M., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a002279 · Cited by 22
“Glu545Gln), the proposed management was to proceed with the PIK3CA inhibitors, taselisib or pictilisib, at disease progression (Turner et al. 2015).”
Kettner, N. M., Bui, T. N., Navarro-Yepes, J., Ghotbaldini, S., Quintela, B., Luo, C. K., Lam, N., Rao, X., Raghavendra, A. S., Wang, Y., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01041-1 · Cited by 27
Updates on managing advanced breast cancer with palbociclib combination therapy
McShane, T. M., Wolfe, T. A., & Ryan, J. C. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793849 · Cited by 21
Zhu, W., & Xu, B. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0795-4 · Cited by 22
Bolzacchini, E., Pomero, F., Fazio, M., Civitelli, C., Fabro, G., Pellegrino, D., Giordano, M., & Squizzato, A. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.009 · Cited by 21
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
Krishnamurthy, J., Luo, J. R., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., Clifton, K., Weilbaecher, K. N., Frith, A. E., Roshal, A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00399-w · Cited by 23
Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L. V., George, S. H. L., & Badal, S. A. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01551-x · Cited by 23
Xu, H., Wang, Y., Han, Y., Wu, Y., Wang, J., & Xu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956464 · Cited by 24
Watson, N. W., Shatzel, J. J., & Al-Samkari, H. T. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.001 · Cited by 22
Shao, H., Zhao, M., Guan, A., Shao, T., Zhou, D., Yu, G., & Tang, W. (2024) · BMC Medicine · doi:10.1186/s12916-023-03238-2 · Cited by 21
Naji, O., Ghouzlani, A., Rafii, S., Sadiqi, R. U., Kone, A.-S., Harmak, Z., Choukri, K., Kandoussi, S., Karkouri, M., & Badou, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399754 · Cited by 23
“Palbociclib is a novel, orally active pyridopyrimidine compound, which is highly selective reversible inhibitor of CDK4/6 (171).”
BackgroundChen, C., Chen, Z., Zhao, J., Wen, X., Yao, H., Weng, Z., Xiong, H., Zheng, Z., & Wu, J. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02336-9 · Cited by 22
Palbociclib for the treatment of postmenopausal breast cancer – an update
Steger, G. G., Gnant, M., & Bartsch, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1133590 · Cited by 21
BELL, T. J., Crown, J. P., Láng, I., Bhattacharyya, H., Zanotti, G., Randolph, S., Kim, S., Huang, X., Bartlett, C. H., Finn, R. S., et al. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1157060 · Cited by 21
Self-citationKiesewetter, B., Raderer, M., Steger, G. G., Bartsch, R., Pirker, R., Zöchbauer‐Müller, S., Prager, G. W., Krainer, M., Preusser, M., Schmidinger, M., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000066 · Cited by 23
New agents for endocrine resistance in breast cancer
Maurer, C., Martel, S., Zardavas, D., & Ignatiadis, M. (2017) · The Breast · doi:10.1016/j.breast.2017.04.007 · Cited by 22
Palbociclib enhances activin‐ SMAD ‐induced cytostasis in estrogen receptor‐positive breast cancer
Harada, M., Morikawa, M., Ozawa, T., Kobayashi, M., Tamura, Y., Takahashi, K., Tanabe, M., Tada, K., Seto, Y., Miyazono, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13841 · Cited by 22
Battisti, N. M. L., Kingston, B., King, J. P., Denton, A. S., Waters, S. H., Sita-Lumsden, A. R., Rehman, F. L., Stavraka, C., Kristeleit, H., Sawyer, E. J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05134-x · Cited by 22
Nuclear localization of p65 reverses therapy-induced senescence
Salunkhe, S. J., Mishra, S. V., Nair, J., Shah, S. G., Gardi, N., Thorat, R. A., Sarkar, D., Rajendra, J., Kaur, E., & Dutt, S. (2021) · Journal of Cell Science · doi:10.1242/jcs.253203 · Cited by 21
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.